Immunotherapy - Vaccines for Allergic Diseases

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2012 Jul 27

PMID 22833826

Citations 10

Authors

Adrian Young-Yuen Wu

Affiliations

Soon will be listed here.

Abstract

Allergic diseases are some of the most commonly encountered problems in clinical practice. Drugs such as corticosteroids and antihistamines can provide effective symptomatic relief, but do not alter the course of the disease. Specific immunotherapy (SIT) was first used to treat pollen allergy in 1911, and has since evolved into an effective treatment for allergic rhinitis and asthma. SIT has been shown in clinical studies to reduce symptoms and medication use in patients with allergic rhinitis and asthma. Recent studies also showed that the therapeutic benefit is long-lasting after the completion of three to five years of treatment. SIT can also effectively reduce the risk of developing asthma and new allergic sensitizations in children with allergic rhinitis.

Citing Articles

Interpreting epidemiologic distribution of total and specific IgE levels for food allergy in Southern China from 2004 to 2023: understanding the mechanisms and focusing on prevention.

Liu M, Liu L, Qi W, Zheng X, Chen J, Yao J BMC Public Health. 2024; 24(1):3022.

PMID: 39482634 PMC: 11529331. DOI: 10.1186/s12889-024-20470-4.

Study of Allergen Patterns in Cases of Moderate to Severe Persistent Allergic Rhinitis in Central India.

Jain S, Jain A, Gupta S Indian J Otolaryngol Head Neck Surg. 2022; 74(Suppl 2):888-893.

PMID: 36452541 PMC: 9702131. DOI: 10.1007/s12070-020-01954-2.

Human immunology and immunotherapy: main achievements and challenges.

Varade J, Magadan S, Gonzalez-Fernandez A Cell Mol Immunol. 2020; 18(4):805-828.

PMID: 32879472 PMC: 7463107. DOI: 10.1038/s41423-020-00530-6.

Nanotechnology-Based Vaccines for Allergen-Specific Immunotherapy: Potentials and Challenges of Conventional and Novel Adjuvants under Research.

Johnson L, Duschl A, Himly M Vaccines (Basel). 2020; 8(2).

PMID: 32443671 PMC: 7349961. DOI: 10.3390/vaccines8020237.

DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy.

Chi Q, Yang Z, Xu K, Wang C, Liang H Front Pharmacol. 2020; 10:1585.

PMID: 32063844 PMC: 6997790. DOI: 10.3389/fphar.2019.01585.

References

Naclerio R, Proud D, Moylan B, Balcer S, Freidhoff L, Lichtenstein L . A double-blind study of the discontinuation of ragweed immunotherapy. J Allergy Clin Immunol. 1997; 100(3):293-300. DOI: 10.1016/s0091-6749(97)70240-9. View

Walker S, Varney V, Gaga M, Jacobson M, Durham S . Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy. 1995; 50(5):405-13. DOI: 10.1111/j.1398-9995.1995.tb01170.x. View

Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, von Berg A . Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002; 109(2):274-80. DOI: 10.1067/mai.2002.121949. View

Durham S, Walker S, Varga E, Jacobson M, OBrien F, Noble W . Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341(7):468-75. DOI: 10.1056/NEJM199908123410702. View

Zielen S, Kardos P, Madonini E . Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010; 126(5):942-9. DOI: 10.1016/j.jaci.2010.06.002. View

Kremer B, Den Hartog H, Jolles J . Relationship between allergic rhinitis, disturbed cognitive functions and psychological well-being. Clin Exp Allergy. 2002; 32(9):1310-5. DOI: 10.1046/j.1365-2745.2002.01483.x. View

Blumberga G, Groes L, Haugaard L, Dahl R . Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy. 2006; 61(7):843-8. DOI: 10.1111/j.1398-9995.2006.01088.x. View

Frankland A, Augustin R . Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component. Lancet. 1954; 266(6821):1055-7. DOI: 10.1016/s0140-6736(54)91620-7. View

Varney V, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew A . Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin Exp Allergy. 1997; 27(8):860-7. View

10.

Tabar A, Arroabarren E, Echechipia S, Garcia B, Martin S, Alvarez-Puebla M . Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol. 2011; 127(1):57-63, 63.e1-3. DOI: 10.1016/j.jaci.2010.10.025. View

11.

Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I . Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2010; 127(1 Suppl):S1-55. DOI: 10.1016/j.jaci.2010.09.034. View

12.

Amin H, Liss G, Bernstein D . Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol. 2006; 117(1):169-75. DOI: 10.1016/j.jaci.2005.10.010. View

13.

Johnstone D . Study of the role of antigen dosage in the treatment of pollenosis and pollen asthma. AMA J Dis Child. 1957; 94(1):1-5. DOI: 10.1001/archpedi.1957.04030020003001. View

14.

Lockey R, Benedict L, Turkeltaub P, BUKANTZ S . Fatalities from immunotherapy (IT) and skin testing (ST). J Allergy Clin Immunol. 1987; 79(4):660-77. DOI: 10.1016/s0091-6749(87)80164-1. View

15.

Haugaard L, Dahl R, Jacobsen L . A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol. 1993; 91(3):709-22. DOI: 10.1016/0091-6749(93)90190-q. View

16.

Nielsen L, Johnsen C, Mosbech H, Poulsen L, Malling H . Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol. 1996; 97(6):1207-13. DOI: 10.1016/s0091-6749(96)70186-0. View

17.

Hedlin G, Heilborn H, Lilja G, Norrlind K, PEGELOW K, Schou C . Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol. 1995; 96(6 Pt 1):879-85. DOI: 10.1016/s0091-6749(95)70223-7. View

18.

Brozek J, Bousquet J, Baena-Cagnani C, Bonini S, Canonica G, Casale T . Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010; 126(3):466-76. DOI: 10.1016/j.jaci.2010.06.047. View

19.

Laffer S, Valenta R, Vrtala S, Susani M, Van Ree R, Kraft D . Complementary DNA cloning of the major allergen Phl p I from timothy grass (Phleum pratense); recombinant Phl p I inhibits IgE binding to group I allergens from eight different grass species. J Allergy Clin Immunol. 1994; 94(4):689-98. DOI: 10.1016/0091-6749(94)90176-7. View

20.

Pajno G, Barberio G, De Luca F, Morabito L, Parmiani S . Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001; 31(9):1392-7. DOI: 10.1046/j.1365-2222.2001.01161.x. View